Makindo Medical Notes.com |
|
---|---|
Download all this content in the Apps now Android App and Apple iPhone/Pad App | |
MEDICAL DISCLAIMER:The contents are under continuing development and improvements and despite all efforts may contain errors of omission or fact. This is not to be used for the assessment, diagnosis or management of patients. It should not be regarded as medical advice by healthcare workers or laypeople. It is for educational purposes only. Please adhere to your local protocols. Use the BNF for drug information. If you are unwell please seek urgent healthcare advice. If you do not accept this then please do not use the website. Makindo Ltd |
Related Subjects: |Assessing Breathlessness |Fever - Pyrexia of unknown origin |TB Meningitis |Lady Windermere syndrome
Stage | Description |
---|---|
Inhalation of Mycobacterium tuberculosis | TB begins when a person inhales airborne droplets containing Mycobacterium tuberculosis. These droplets reach the alveoli of the lungs, where the bacteria are engulfed by alveolar macrophages. |
Bacterial Replication | Inside the alveolar macrophages, M. tuberculosis can replicate due to its ability to resist the bactericidal mechanisms of the macrophages. This is facilitated by the bacteria's lipid-rich cell wall, which prevents destruction by lysosomal enzymes. |
Formation of Primary Lesion (Ghon Focus) | The initial site of infection in the lung is known as the Ghon focus. If the bacteria spread to the regional lymph nodes, the combination of the Ghon focus and the affected lymph nodes is referred to as the Ghon complex. |
Immune Response and Granuloma Formation | The immune system responds by recruiting more immune cells (e.g., macrophages, T lymphocytes) to the site of infection. These cells form a granuloma, a structured collection of immune cells that attempt to contain the infection. Within the granuloma, the bacteria can become dormant, leading to latent TB infection. |
Caseation Necrosis | Over time, the center of the granuloma may undergo caseation necrosis, where the tissue becomes soft and cheese-like. This necrotic tissue can break down, allowing the bacteria to spread within the lung or to other parts of the body. |
Potential Outcomes |
Latent TB: If the immune system successfully contains the bacteria, TB remains in a latent state, with the bacteria dormant and the person asymptomatic.
Active TB: If the immune system is compromised, or over time, the bacteria can reactivate, leading to active TB, where the person exhibits symptoms and can transmit the disease. |
Dissemination | In some cases, especially in immunocompromised individuals, the bacteria may disseminate through the bloodstream to other organs, causing miliary TB or extrapulmonary TB (e.g., in the bones, kidneys, or brain). |
Tissue Damage and Clinical Manifestations | The ongoing immune response and bacterial activity lead to tissue damage, which causes the clinical manifestations of TB, such as chronic cough, haemoptysis (coughing up blood), weight loss, and fever. |
Manifestation | Description | Common Symptoms | Diagnostic Methods |
---|---|---|---|
Primary TB | The initial infection with Mycobacterium tuberculosis, often occurring in children. It may be asymptomatic or present with mild symptoms. | Mild fever, malaise, cough, or can be asymptomatic. Ghon complex may be visible on X-ray. | Tuberculin skin test (TST), chest X-ray, sputum culture (though often negative in primary TB). |
Post-Primary (Reactivation) TB | Occurs when latent TB becomes active, typically in adults, and primarily affects the upper lobes of the lungs. | Persistent cough, haemoptysis (coughing up blood), night sweats, weight loss, fever. | Chest X-ray, sputum smear microscopy, molecular tests (e.g., GeneXpert), culture. |
Pulmonary TB | The most common form of TB that primarily affects the lungs. It is contagious and can spread through airborne particles. | Persistent cough, chest pain, coughing up blood, fatigue, weight loss, fever, night sweats. | CXR, sputum smear microscopy, molecular tests, culture. |
Extrapulmonary TB | TB that occurs in organs other than the lungs, such as lymph nodes, pleura, bones, joints, genitourinary system, and the brain. | Symptoms vary depending on the affected organ, such as lymphadenopathy, pleuritic chest pain, abdominal pain, joint pain, headache, etc. | Imaging studies (CT, MRI), biopsy, molecular tests, culture, fluid analysis (e.g., pleural fluid, cerebrospinal fluid). |
CNS TB | Tuberculosis that affects the central nervous system, including tuberculous meningitis, tuberculomas, and spinal TB (Pott's disease). | Headache, neck stiffness, fever, confusion, seizures, focal neurological deficits. | Lumbar puncture (CSF analysis), MRI or CT of the brain, molecular tests, culture of CSF. |
Bone TB (Skeletal TB) | TB infection in bones and joints, commonly affecting the spine (Pott's disease), hips, and knees. | Chronic pain in affected bones, deformities, swelling, reduced mobility, systemic symptoms like fever and weight loss. | X-rays, MRI or CT of the affected area, biopsy, culture, molecular tests. |
Gastrointestinal (GI) TB | TB infection in the gastrointestinal tract, commonly affecting the ileocecal region but can occur anywhere in the GI tract. | Abdominal pain, weight loss, fever, diarrhea, constipation, bowel obstruction, or perforation. | Endoscopy, biopsy, imaging studies (CT scan), molecular tests, culture of tissue samples. |
Skin TB (Cutaneous TB) | TB infection of the skin, manifesting as various lesions, such as lupus vulgaris, scrofuloderma, or tuberculous chancres. | Chronic skin ulcers, nodules, plaques, or abscesses, often on the face, neck, or extremities. | Skin biopsy, histopathology, culture, molecular tests. |
Miliary TB | A form of TB where bacteria spread throughout the body via the bloodstream, causing tiny nodules to form in various organs. | Generalized weakness, fever, weight loss, difficulty breathing, hepatosplenomegaly. | Chest X-ray (miliary pattern), blood cultures, bone marrow biopsy, liver biopsy, molecular tests. |
Latent TB | A condition where the TB bacteria are present in the body but inactive, and the person does not have symptoms. However, it can activate and become active TB. | No symptoms, as the bacteria are dormant. | Tuberculin skin test (TST), Interferon-Gamma Release Assays (IGRAs). |
Drug-Resistant TB | TB caused by bacteria that are resistant to at least one of the main anti-TB drugs (such as isoniazid or rifampin). Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are more severe forms. | Similar to pulmonary TB but with poor response to standard treatment. | Drug susceptibility testing (DST), molecular tests, culture. |
TB in Other Organs | TB can affect almost any organ in the body, including the liver, spleen, adrenal glands, and eyes. | Symptoms vary depending on the organ affected; may include organ-specific symptoms like jaundice (liver), adrenal insufficiency, or vision problems (ocular TB). | Imaging studies (e.g., ultrasound, CT, MRI), biopsy, culture, molecular tests specific to the affected organ. |
Stage | Immune Response | Details |
---|---|---|
Innate Immune Response | Macrophage Activation | Upon inhalation of Mycobacterium tuberculosis, alveolar macrophages are the first line of defense. They recognize the bacteria via pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs). Macrophages engulf the bacteria through phagocytosis. |
Macrophage Response | Phagosome-Lysosome Fusion | After engulfment, the bacteria are contained within a phagosome, which fuses with a lysosome to form a phagolysosome. The acidic environment and digestive enzymes are intended to kill the bacteria. However, M. tuberculosis can inhibit this fusion and survive within macrophages. |
Adaptive Immune Response | Antigen Presentation and T Cell Activation | Infected macrophages present M. tuberculosis antigens on their surface via MHC class II molecules. This leads to the activation of CD4+ T helper cells, which secrete cytokines, particularly IFN-γ, to enhance the macrophage's ability to kill the bacteria. |
T Helper Cell Response | Th1 Response and Cytokine Production | The dominant immune response in TB is the Th1 response. CD4+ T cells produce IFN-γ, which activates macrophages to increase their antimicrobial activity. This cytokine response is crucial for containing the infection within granulomas. |
Granuloma Formation | Formation of Granulomas | To contain the infection, the immune system forms granulomas. These are structured aggregates of immune cells, including macrophages, T cells, and sometimes B cells. Within granulomas, macrophages may differentiate into multinucleated giant cells or foam cells, and a caseous necrotic core may develop. |
Latent TB | Maintenance of Latency | In latent TB, the immune system successfully contains the bacteria within granulomas, preventing active disease. This state of dormancy is maintained by a balance between bacterial persistence and immune surveillance, primarily involving T cells and cytokines like TNF-α and IFN-γ. |
Reactivation TB | Breakdown of Immune Control | If the immune system is weakened (e.g., due to HIV, aging, or immunosuppressive therapy), the granulomas may break down, releasing viable bacteria and leading to reactivation of TB. This can cause active TB disease, with symptoms and the potential for transmission. |
Immune Evasion | Evasion of Host Defenses | M. tuberculosis employs several strategies to evade the immune system, including inhibiting phagosome-lysosome fusion, resisting reactive oxygen and nitrogen species, and modulating host cell death pathways to avoid killing. |
Systemic Immune Response | Cytokine Release and Inflammation | The systemic immune response involves the release of cytokines such as TNF-α, IL-1, and IL-12, which mediate fever, weight loss, and other systemic symptoms of TB. Chronic inflammation can lead to tissue damage and fibrosis. |
Investigation | Description | Details |
---|---|---|
Sputum Smear Microscopy | Sputum microscopy after staining with Ziehl-Neelsen or auramine-rhodamine stain to identify acid-fast bacilli (AFB). | This is rapid and inexpensive. Sensitivity is higher in cases with a high bacterial load. Limited by its inability to differentiate between Mycobacterium tuberculosis and non-tuberculous mycobacteria. |
Sputum Culture | Culturing sputum samples on solid (e.g., Löwenstein-Jensen) or liquid media (e.g., MGIT) to grow and identify Mycobacterium tuberculosis. | Considered the gold standard for TB diagnosis. More sensitive than smear microscopy. Can take 2-8 weeks for results due to the slow growth of M. tuberculosis. Allows for drug susceptibility testing. |
GeneXpert MTB/RIF | A nucleic acid amplification test (NAAT) that detects Mycobacterium tuberculosis DNA and resistance to rifampin (RIF) directly from sputum samples. | Rapid (results within 2 hours). High sensitivity and specificity. Can detect rifampin resistance, which is a marker for multidrug-resistant TB (MDR-TB). |
Tuberculin Skin Test (TST) | Also known as the Mantoux test, this involves intradermal injection of purified protein derivative (PPD) to assess delayed-type hypersensitivity reaction. | - Used to detect latent TB infection. Results are read 48-72 hours after injection. False positives can occur due to BCG vaccination or non-tuberculous mycobacteria. False negatives can occur in immunocompromised individuals. |
Interferon-Gamma Release Assays (IGRAs) | Blood tests (e.g., QuantiFERON-TB Gold, T-SPOT.TB) that measure the immune response to TB antigens by detecting interferon-gamma release from T cells. | Used to detect latent TB infection. More specific than TST, with no cross-reactivity with BCG vaccine. Results available within 24 hours. Cannot differentiate between latent and active TB. |
Chest X-ray | Imaging study used to detect lung abnormalities suggestive of TB, such as cavitations, infiltrates, and nodules. | Useful for detecting pulmonary TB. Can show abnormalities even in asymptomatic individuals. - Not specific for TB; other lung conditions can cause similar findings. Often used in conjunction with other tests for diagnosis. |
CT Scan | Computed tomography scan provides more detailed images of the lungs and other organs, helping to identify the extent and nature of TB involvement. | More sensitive than chest X-ray for detecting small lesions or extrapulmonary TB. Can detect complications such as pleural effusion or lymphadenopathy. Higher radiation exposure and cost compared to chest X-ray. |
Bronchoscopy | An invasive procedure where a bronchoscope is inserted into the airways to obtain samples (e.g., bronchoalveolar lavage, biopsy) from the lungs. | Useful when sputum samples are negative or when TB is suspected in patients unable to produce sputum. Can help diagnose extrapulmonary or endobronchial TB. Involves some risk, including infection and bleeding. |
Histopathology | Microscopic examination of biopsy tissue to detect granulomas, caseous necrosis, and the presence of acid-fast bacilli. | Important for diagnosing extrapulmonary TB (e.g., lymph nodes, bones, kidneys). Can confirm TB in tissues where other tests are inconclusive. Requires invasive procedures to obtain tissue samples. |
Drug Susceptibility Testing (DST) | Laboratory tests performed on cultured M. tuberculosis to determine resistance to anti-TB drugs. | Essential for guiding treatment, especially in cases of drug-resistant TB. Can be performed on solid or liquid cultures. Takes additional time after culture growth. |
Pleural Fluid Analysis | Examination of pleural fluid obtained via thoracentesis to diagnose TB pleuritis. | Can detect lymphocytic pleocytosis, elevated protein, and adenosine deaminase (ADA) levels indicative of TB. May require biopsy for confirmation. |
Management Aspect | Description |
---|---|
Diagnosis |
|
Pharmacotherapy |
|
Adherence Monitoring |
|
Adverse Effect Management |
|
Infection Control |
|
Follow-up |
|
Prevention |
|
Type of TB | Standard Treatment Regimen | Duration | Additional Notes |
---|---|---|---|
Drug-Sensitive Pulmonary TB |
|
6 months total:
2 months (initial phase) + 4 months (continuation phase) |
Directly Observed Therapy (DOT) is recommended to ensure adherence. |
Latent TB |
|
3-9 months, depending on the regimen. | Treatment choice depends on patient factors, including potential drug interactions. |
Multidrug-Resistant TB (MDR-TB) | Individualized treatment based on drug susceptibility testing (DST). Commonly includes a combination of fluoroquinolones, second-line injectable drugs (e.g., amikacin), and newer drugs like bedaquiline or linezolid. | 18-24 months or longer, depending on response and regimen. | Requires close monitoring for drug toxicity and treatment adherence. |
Extensively Drug-Resistant TB (XDR-TB) | Individualized treatment based on DST, often including newer drugs such as bedaquiline, linezolid, and delamanid, along with other second-line agents. | 24 months or longer. | Management in specialized centers is recommended due to complexity and severity. |
CNS TB (e.g., TB Meningitis) | Standard TB drugs (INH, RIF, PZA, EMB) with adjunctive corticosteroids (e.g., dexamethasone or prednisone) to reduce inflammation. | 9-12 months, with the duration of corticosteroids tapered over weeks. | Requires early diagnosis and treatment to prevent severe neurological sequelae. |
Bone and Joint TB | Standard TB drugs (INH, RIF, PZA, EMB). May require surgical intervention in severe cases. | 9-12 months. | Monitoring for bone healing and response to therapy is essential. |
Pregnancy and TB | Standard TB drugs (INH, RIF, EMB). PZA is often included, but its use depends on regional guidelines. | 6-9 months. | Streptomycin and other aminoglycosides are contraindicated due to potential teratogenic effects. |
HIV and TB Co-infection | Standard TB drugs (INH, RIF, PZA, EMB) along with antiretroviral therapy (ART). ART typically includes a combination of drugs such as tenofovir, lamivudine, and efavirenz. | 6 months or longer depending on TB severity and patient response. | Start ART as soon as possible after initiating TB treatment, usually within the first 2-8 weeks. Monitoring for drug interactions and immune reconstitution inflammatory syndrome (IRIS) is essential. |
Phase | Drug | Dosage | Duration |
---|---|---|---|
Initial Phase | Isoniazid | 300 mg daily | 2 months |
Rifampin (Rifampicin) | 600 mg daily | 2 months | |
Pyrazinamide | 1500 mg daily | 2 months | |
Ethambutol | 1200 mg daily | 2 months | |
Continuation Phase | Isoniazid | 300 mg daily | 4-7 months |
Rifampin (Rifampicin) | 600 mg daily | 4-7 months |
Drug | Typical Dose | Common Side Effects |
---|---|---|
Isoniazid (INH) |
Adults: 5 mg/kg daily (typically 300 mg/day)
Children: 10-15 mg/kg daily (maximum 300 mg/day) |
Hepatotoxicity, peripheral neuropathy, rash, fever, drug-induced lupus. |
Rifampicin (Rifampin) (RIF) |
Adults: 10 mg/kg daily (typically 600 mg/day)
Children: 10-20 mg/kg daily (maximum 600 mg/day) |
Hepatotoxicity, orange discoloration of body fluids, gastrointestinal upset, flu-like symptoms, drug interactions. |
Pyrazinamide (PZA) |
Adults: 15-30 mg/kg daily (typically 1.5-2 g/day)
Children: 15-30 mg/kg daily (maximum 2 g/day) |
Hepatotoxicity, hyperuricemia (can lead to gout), arthralgia, gastrointestinal upset. |
Ethambutol (EMB) |
Adults: 15-25 mg/kg daily (typically 800-1600 mg/day depending on weight)
Children: 15-25 mg/kg daily (maximum 1600 mg/day) |
Optic neuritis (can cause visual disturbances and color blindness), gastrointestinal upset, peripheral neuropathy. |
Streptomycin |
Adults: 15 mg/kg daily (maximum 1 g/day)
Children: 20-40 mg/kg daily (maximum 1 g/day) |
Ototoxicity (hearing loss), nephrotoxicity, vestibular toxicity (balance issues), injection site pain. |
Bedaquiline |
Adults: 400 mg daily for 2 weeks, then 200 mg three times a week
Not typically used in children unless under special circumstances |
QT prolongation (can lead to serious heart arrhythmias), nausea, joint pain, headache. |
Linezolid |
Adults: 600 mg twice daily
Children: 10 mg/kg every 8-12 hours |
Bone marrow suppression, peripheral and optic neuropathy, lactic acidosis, gastrointestinal upset. |
Levofloxacin |
Adults: 500-750 mg daily
Children: 10-20 mg/kg daily (maximum 750 mg/day) |
Tendonitis and tendon rupture, QT prolongation, gastrointestinal upset, dizziness, insomnia. |
Clofazimine |
Adults: 100 mg daily
Children: 1-2 mg/kg daily (maximum 100 mg/day) |
Skin discoloration (red-brown), gastrointestinal upset, dry skin, photosensitivity. |